Molecular Mechanisms of Castrate-Resistant Prostate Cancer.

Journal Article (Journal Article;Review)

Despite newer therapies for castrate-resistant prostate cancer (CRPC), many patients do not experience a treatment response, and most eventually experience secondary resistance. Various androgen-receptor-related and alternative mechanisms of resistance in CRPC have been identified. This focus on understanding the molecular basis of therapeutic resistance, including lineage plasticity, neuroendocrine transformation, and a range of other implicated genomic alterations will hopefully inform decision-making in the care of this lethal cancer.

Full Text

Duke Authors

Cited Authors

  • Kotamarti, S; Armstrong, AJ; Polascik, TJ; Moul, JW

Published Date

  • November 2022

Published In

Volume / Issue

  • 49 / 4

Start / End Page

  • 615 - 626

PubMed ID

  • 36309418

Electronic International Standard Serial Number (EISSN)

  • 1558-318X

Digital Object Identifier (DOI)

  • 10.1016/j.ucl.2022.07.005


  • eng

Conference Location

  • United States